Growth Metrics

Novartis Ag (NVS) Shares Outstanding (Diluted Average) (2009 - 2026)

Novartis Ag recorded quarterly Shares Outstanding (Diluted Average) of $1.6 million in Q1 2026, down 76.92% quarter-over-quarter from $7.2 million in Q4 2025, and down 9.34% year-over-year from $1.8 million in Q1 2025.

Novartis Ag's Shares Outstanding (Diluted Average) history runs 18 years deep, the most recent figure standing at $1.6 million for Q1 2026.

  • In Q1 2026, Shares Outstanding (Diluted Average) fell 9.34% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (down 9.34% YoY), while the FY2025 annual figure was $7.2 million, up 21.81% from the prior year.
  • Shares Outstanding (Diluted Average) came in at $1.6 million for Q1 2026 at Novartis Ag, down from $7.2 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $7.2 million in Q4 2025 to a low of $990000.0 in Q1 2022.
  • A 5-year average of $3.0 million and a median of $2.8 million in 2022 frame the typical range for Shares Outstanding (Diluted Average).
  • Across the five-year window, Shares Outstanding (Diluted Average) sank 74.13% in 2022 and soared 165.14% in 2024, its largest moves.
  • Novartis Ag's Shares Outstanding (Diluted Average) stood at $2.8 million in 2022, then jumped by 49.09% to $4.1 million in 2023, then soared by 43.17% to $5.9 million in 2024, then advanced by 21.81% to $7.2 million in 2025, then sank by 76.92% to $1.6 million in 2026.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods registered $1.6 million, $7.2 million, and $5.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares (Diluted Avg.) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - 1.65 Mn
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 895.90 Mn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 2.45 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 1.77 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 544.00 Mn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 1.25 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 5.73 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 1.65 Mn
Dec 31, 2025 7.15 Mn
Sep 30, 2025 5.90 Mn
Jun 30, 2025 3.88 Mn
Mar 31, 2025 1.82 Mn
Dec 31, 2024 5.87 Mn
Sep 30, 2024 4.46 Mn
Jun 30, 2024 2.89 Mn
Mar 31, 2024 1.31 Mn
Dec 31, 2023 4.10 Mn
Sep 30, 2023 2.83 Mn
Jun 30, 2023 1.09 Mn
Mar 31, 2023 1.01 Mn
Dec 31, 2022 2.75 Mn
Sep 30, 2022 2.14 Mn
Jun 30, 2022 1.76 Mn
Mar 31, 2022 990,000.00
Dec 31, 2021 10.63 Mn
Sep 30, 2021 3.41 Mn
Jun 30, 2021 2.19 Mn
Mar 31, 2021 910,000.00
Dec 31, 2020 3.52 Mn
Sep 30, 2020 2.60 Mn
Jun 30, 2020 1.76 Mn
Mar 31, 2020 950,000.00
Dec 31, 2019 3.08 Mn
Sep 30, 2019 2.59 Mn
Jun 30, 2019 900,000.00
Mar 31, 2019 760,000.00
Dec 31, 2018 5.38 Mn
Sep 30, 2018 4.87 Mn
Jun 30, 2018 3.29 Mn
Mar 31, 2018 840,000.00
Dec 31, 2017 3.25 Mn
Sep 30, 2017 2.41 Mn
Jun 30, 2017 830,000.00
Mar 31, 2017 700,000.00
Dec 31, 2016 2.40 Bn
Sep 30, 2016 2.40 Mn
Jun 30, 2016 750,000.00
Mar 31, 2016 840,000.00
Dec 31, 2015 2.88 Mn
Sep 30, 2015 2.44 Mn
Jun 30, 2015 750,000.00
Mar 31, 2015 940,000.00
Dec 31, 2014 4.31 Mn
Sep 30, 2014 3.32 Mn
Jun 30, 2014 1.03 Mn
Mar 31, 2014 970,000.00
Dec 31, 2013 3.70 Mn
Sep 30, 2013 900,000.00
Jun 30, 2013 1.01 Mn
Mar 31, 2013 970,000.00
Sep 30, 2012 3.06 Mn
Jun 30, 2012 2.05 Mn
Mar 31, 2012 950,000.00
Dec 31, 2011 3.78 Mn
Sep 30, 2011 3.30 Mn
Jun 30, 2011 1.11 Mn
Mar 31, 2011 1.20 Mn
Dec 31, 2010 4.26 Mn
Sep 30, 2010 3.32 Mn
Jun 30, 2010 1.05 Mn
Mar 31, 2010 1.28 Mn
Dec 31, 2009 3.69 Mn
Sep 30, 2009 2.67 Mn
Jun 30, 2009 890,000.00
Mar 31, 2009 860,000.00